News by Subject Medicine & Health

Researchers from the Icahn School of Medicine used a novel genetic sequencing technology to identify the genetic cause of--and a treatment for--a previously unknown severe auto inflam-matory syndrome affecting an 18-year-old girl since infancy.

A new study led by scientists at La Jolla Institute for Immunology (LJI) shows that memory helper T cells that recognize common cold coronaviruses also recognize matching sites on SARS-CoV-2, the virus that causes COVID-19.

New research from University of Sydney finds COVID-19 transmission rates in NSW schools and early childcare education and care settings were minimal, particularly between children and from children to adults.

Since the discovery of COVID-19, a warlike analogy is frequently used to define our interaction with the virus, but in many ways we may be at war with ourselves.

Scientists at UCL have discovered new biomarkers, which may identify those people with Type 1 diabetes who would benefit from the immunotherapy drug Abatacept, a finding which could eventually help thousands manage the disease more effectively.

New genetic and patient analyses suggest severe COVID is linked to overactive complement, one of the immune system's oldest branches, and excess blood clotting.

Immunization programs offered in low- and middle-income countries provide a high "return on investment" in terms of the economic costs of diseases that are prevented and the values of lives that would have been lost.

Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits.

Professor Shabir A. Madhi of the University of the Witwatersrand, Johannesburg, is the lead author of a study published in the prestigious New England Journal of Medicine on Thursday, 30 July 2020. The multinational, multicentre study reports on the first RSV vaccine to provide evidence that inmunisation of pregnant woman could protect young infants under six months old against severe RSV lower respiratory tract infection (LRTI).